Alternative Treatment Options for Obstructive Sleep Apnea (OSA)

Understanding the Risks of Untreated OSA

Untreated OSA is associated with significant cardiovascular morbidity, mortality, and decreased quality of life, according to the European Respiratory Review and the American Academy of Sleep Medicine 1, 2
The natural course of untreated OSA typically worsens over time, with increasing AHI and symptom severity, as reported in the European Respiratory Journal 3

The American Academy of Sleep Medicine recommends custom-made dual-block mandibular advancement devices as a first-line alternative for patients with mild to moderate OSA (AHI <30) who refuse CPAP 1, 2
Positional therapy is recommended for patients with positional OSA (lower AHI in non-supine positions), and requires verification of efficacy with polysomnography before initiating as primary therapy, according to the American Academy of Sleep Medicine 4
Hypoglossal nerve stimulation is suggested for patients with moderate to severe OSA (AHI 15-65) with BMI <32 kg/m² who refuse CPAP, as recommended by the American Academy of Sleep Medicine 2
Maxillomandibular advancement surgery can be considered for patients with severe OSA who refuse all other treatments, according to the European Respiratory Journal and the American Academy of Sleep Medicine 2, 3

The American Academy of Sleep Medicine recommends weight loss for all overweight OSA patients, though rarely curative as monotherapy, and suggests follow-up sleep study after substantial weight loss (≥10% of body weight) to reassess treatment needs 4
Avoidance of alcohol and sedatives before bedtime can improve OSA symptoms, as reported by the American Academy of Sleep Medicine 4

For mild to moderate OSA (AHI <30), the American Academy of Sleep Medicine recommends custom-made mandibular advancement device as first alternative, and positional therapy if positional OSA is confirmed 1, 2, 4
For moderate to severe OSA (AHI ≥30), the American Academy of Sleep Medicine suggests hypoglossal nerve stimulation if BMI <32 kg/m² and AHI 15-65, and maxillomandibular advancement for young patients without excessive BMI 2, 3

The American Academy of Sleep Medicine recommends documenting the patient's understanding of the increased risks of untreated OSA, including cardiovascular complications and mortality, and the superior efficacy of CPAP compared to alternative treatments 1, 2
The patient's understanding of the specific alternative treatment options recommended based on their OSA severity and characteristics, and the importance of follow-up to assess treatment efficacy, should also be documented, as suggested by the American Academy of Sleep Medicine 1, 2, 4

The European Respiratory Society recommends custom-made dual-block mandibular advancement devices (MADs) as the first-line alternative for mild to moderate OSA, with 13 randomized controlled trials showing the highest level of evidence among alternatives 5, 6
Patient-related outcomes, such as sleepiness and quality of life, are equivalent between CPAP and MADs, justifying MADs as a reasonable first alternative 5, 6
Vibratory positional therapy can be considered for patients with documented lower AHI in non-supine positions, although it has very low certainty evidence 5, 7
Hypoglossal nerve stimulation (HNS) received a conditional recommendation against first-line use, but can be used after CPAP failure following strict eligibility criteria, including AHI 15-65 events/hour and BMI <32 kg/m² 5, 6
Maxillomandibular advancement (MMO) can be considered as salvage therapy after CPAP failure, but requires surgical expertise and has significant perioperative considerations 5, 6

The European Respiratory Society suggests that combination therapies may be a promising pathophysiological rationale, but evidence remains preliminary 5, 6
Gastric bypass surgery has no randomized trials comparing to CPAP available, but may be considered in selected cases 5, 7

Soft palate surgery alone lacks substantial evidence for efficacy and was excluded from recent guidelines 6
Tongue-retaining devices should not be used routinely, but only for selected mild-to-moderate OSA patients when other treatments have failed 6
Complete concentric collapse at the soft palate predicts failure of HNS, and DISE should not be skipped before HNS 5, 6
MADs are significantly less effective than CPAP for AHI reduction in severe disease, although the clinical significance depends on patient-centered outcomes 5, 6
Health inequity is a concern, as high costs of HNS and limited availability of specialized surgical expertise create access barriers 5, 7

The European Respiratory Review recommends custom-made dual-block mandibular advancement devices (MADs) as the highest-evidence alternative to CPAP for severe OSA, despite showing inferior AHI reduction compared to CPAP 8
MADs demonstrate equivalent patient-related outcomes, such as sleepiness and quality of life, to CPAP, despite less AHI reduction 8
A critical limitation of MADs is that they are significantly less effective than CPAP for AHI reduction in severe OSA, which may not meet DOT requirements for adequate treatment 8

The American Academy of Sleep Medicine recommends that alternative treatments, such as MADs, should demonstrate objective treatment efficacy through follow-up sleep studies showing significant AHI reduction, and documented adherence to the prescribed treatment 8